Business Context and Reporting Period
Company: DAXOR CORP
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2003
Business Overview: DAXOR operates in two primary segments: the marketing and sale of the BVA-100 Blood Volume Analyzer and associated kits, and localized semen and blood banking services. The company is actively expanding its sales and marketing force to establish blood volume measurement as a standard of care.
Key Financial Metrics
| Metric | Six Months Ended June 30, 2003 | Six Months Ended June 30, 2002 |
|---|---|---|
| Total Revenues | $1,509,284 | $1,414,926 |
| Operating Revenues | $509,094 | $389,504 |
| Dividend Income | $910,641 | $908,543 |
| Net Income (Loss) | $(522,239) | $110,665 |
| Net Cash from Operating Activities | $(544,268) | $73,315 |
| Total Assets | $45,557,552 | $41,573,565 |
| Shareholders' Equity | $35,065,290 | $33,546,897 |
| Loans Payable (Debt) | $2,633,309 | $1,434,046 |
| Cash and Cash Equivalents | $60,532 | $13,035 |
Note: Shareholders' Equity includes $14,563,509 in net unrealized holding gains on available-for-sale securities.
Material Changes vs. Prior Period
- Profitability Decline: The company reported a net loss of $522,239 for the six months ended June 30, 2003, compared to a net income of $110,665 in the prior year period. This shift was driven by a significant increase in operating expenses.
- Expense Growth: Selling, General, and Administrative (SG&A) expenses rose to $1,295,354 from $867,771 in the prior year, attributed to the hiring of additional sales and marketing personnel. Operations of Laboratories & Cost of Production also increased to $680,942 from $402,784.
- Revenue Mix: While total revenues increased slightly, operating revenues grew by approximately 31% ($509,094 vs. $389,504). However, the company notes that leasing strategies for the BVA-100 equipment result in slower recognition of operating income compared to direct sales.
- Liquidity and Debt: Cash on hand increased to $60,532 from $13,035. However, debt obligations (loans payable) increased significantly to $2,633,309 from $1,434,046, primarily due to increased margin debt with brokers to purchase investments.
Guidance, Outlook, and Risks
- Strategic Focus: Management anticipates that sales of the BVA-100 Blood Volume Analyzer and kits will become the major source of income. The company plans to hire additional regional managers and expand support services.
- Capital Allocation: Financial reserves will be primarily used for developing and marketing the Blood Volume Analyzer. The company is evaluating options to expand blood banking services.
- Revenue Recognition Risk: The company utilizes an instrument loaner reagent plan and a private label leasing program (Daxor Capital). While these facilitate market penetration, they result in a slower return on capital expenditure and slower recognition of operating income.
- Market Dependency: Future sales growth is partially contingent on the publication of research studies in peer-reviewed medical journals by current users of the Blood Volume Analyzer.
- Investment Portfolio: A significant portion of the company's assets ($44.5 million) consists of marketable securities. While these hold substantial unrealized gains, they are subject to market volatility. Deferred taxes of $7.5 million are recorded based on the potential sale of this portfolio.
Investor Verification Checklist
- Unrealized Gains: Verify the sustainability of the $22 million net unrealized gain on the investment portfolio, which significantly inflates Shareholders' Equity but is not realized cash.
- Debt Structure: Confirm the terms of the $2.6 million in loans payable, specifically the margin debt secured by marketable securities, to assess liquidity risk if the portfolio value declines.
- Operating Cash Flow: Monitor the negative operating cash flow of $(544,268) to ensure the company can sustain its expanded marketing efforts without depleting cash reserves or increasing debt further.
- Revenue Recognition: Assess the impact of the leasing and loaner programs on the timing of revenue recognition for the BVA-100 product line.
- Deferred Taxes: Understand that the $7.5 million deferred tax liability is a non-cash item that would only become payable if the entire investment portfolio were sold.